RPAM
FLNA

Rhenman & Partners Asset Management’s Filana Therapeutics FLNA Stock Holding History

Rhenman & Partners Asset Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-85,000
Closed -$5.28M – 94
2021
Q3 		$5.28M Sell
85,000
-30,000
-26% -$2.5M 0.37% 74
2021
Q2 		$9.83M Buy
+115,000
New +$6.16M 0.67% 57

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rhenman & Partners Asset Management's FLNA Position: Q4 2021 in Review

Rhenman & Partners Asset Management sold out of Filana Therapeutics (FLNA) in Q4 2021, closing a stake of 85,000 shares — an estimated $5.28M sold.

Rhenman & Partners Asset Management first reported a position in FLNA in Q2 2021 and held it in 2 quarters. The position peaked at $9.83M in Q2 2021. 171 funds tracked by Wall St. Rank hold FLNA as of Q4 2021.

  • Rhenman & Partners Asset Management reported no remaining Filana Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 85,000 Filana Therapeutics shares in Q4 2021, an estimated $5.28M.
  • Rhenman & Partners Asset Management first reported a position in Filana Therapeutics in Q2 2021 and held it in 2 quarters.
  • Rhenman & Partners Asset Management's Filana Therapeutics position peaked at $9.83M in Q2 2021.
  • 171 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2021.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.